FREE Daily Stock Alerts From Stock-PR.com
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, announced that it has completed patient enrollment in its second randomized Phase II clinical trial for bavituximab. In this trial, 66 patients with previously untreated genotype-1 hepatitis C virus (HCV) infection were treated with 12 weeks of ribavirin in combination with bavituximab or pegylated interferon alpha-2a. Bavituximab is a phosphatidylserine (PS)-targeting monoclonal antibody with broad therapeutic potential and also is being evaluated in randomized Phase II trials for second-line and front-line NSCLC and pancreatic cancer, as well as in several investigator-sponsored trials (ISTs) in additional oncology indications.
Read full article and disclaimer at : http://stock-pr.com/?p=20176